期刊文献+

TP方案时辰化疗对中晚期非小细胞肺癌患者免疫功能的影响 被引量:4

The Effects of Chrono-Chemotherapy with Paclitaxol puls Cisplatin on Immune Function for Patients with Advanced Non-small Cell Lung Cancer
下载PDF
导出
摘要 目的对比观察TP方案的时辰化疗和常规化疗对中晚期非小细胞肺癌患者的免疫功能的影响。方法 68例经病理学或细胞学确诊的初治中晚期非小细胞肺癌患者,随机分为两组,时辰组(CC组):34例,常规组(RC组):34例。结果时辰化疗组:①CD3+、B细胞较化疗前上升,但差异无显著性(P>0.001);②CD4+、CD4+/CD8+、CD8+CD28+较化疗前有显著上升,差异有显著性(P<0.001);③CD8+、CD8+CD28-、NK细胞较化疗前显著下降,差异有显著性(P<0.001)。常规化疗组:①CD3+、CD4+较化疗前上升,但差异无显著性;②CD8+较化疗前略有上升,但差异无显著性;③CD4+/CD8+、CD8+CD28+、CD8+CD28-较化疗前略有下降,但差异无显著性;④NK细胞、B细胞较化疗前有下降,但差异无显著性(P>0.001)。结论 TP方案时辰化疗近期对患者细胞免疫产生影响,提高了患者的细胞免疫功能,对体液免疫无影响。TP方案时辰化疗是一种治疗中晚期非小细胞肺癌的有效方法。 Objective To compare the effects on patients' immune function of chrono-chemotherapy(paclitaxol puls cisplatin)with routine-chemotherapy for advanced non-small cell lung cancer.Methods Sixty-eight patients with pathological-proved untreated advanced non-small cell lung cancer were randomly divided into the chronological chemotherapy group(group CC,34 cases) and the routine chemotherapy group(group RC,34 cases).Results In the group CC,the CD3+ and B cell were no significant difference between pre-and post-chemotherapy(P0.001),the CD4+,CD4+/CD8+,CD8+CD28+were significantly increased and CD8+,CD8+CD28-,NK cell were significantly decreased in group CC(P0.001).While the changes of the measures of immune function were not signif icant in the group RC(P0.001).Conclusions The short-term immunity effects of chrono-chemotherapy with paclitaxol puls cisplatin is better than that of routine-chemotherapy,it can improve the cellular immune function of patients,and it has no effect on the humoral immunity.So it is recommended to be a better treatment choice of the advanced non-small cell lung cancer.
作者 魏成明
出处 《中国医药指南》 2010年第26期23-25,共3页 Guide of China Medicine
关键词 非小细胞肺癌 时辰化疗 紫杉醇 顺铂 免疫学 Non-small cell lung cancer Chrono-chemotherapy Paclitaxol Cisplatin Immunologic
  • 相关文献

参考文献7

二级参考文献18

  • 1吕纪马,王绿化,周宗玫,张红星,陈东福.放射治疗同步紫杉醇化疗局部晚期非小细胞肺癌的Ⅱ期临床研究[J].中华放射肿瘤学杂志,2004,13(2):89-92. 被引量:68
  • 2王志东,刘斌,邱振华,刘红兵.多西他赛每周用药时辰化疗治疗老年晚期非小细胞肺癌的临床研究[J].肿瘤防治杂志,2005,12(11):853-855. 被引量:17
  • 3谷铣芝.肿瘤放射治疗学[M].北京:北京医科大学、中国协和医科大学联合出版社,1993.399.
  • 4Roobert F,Spencer S,Childs H A 3 rd,et al.Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer:long-term follow-up of a phase Ⅰ trail[J].Lung Cancer,2002,37 (2):189-199.
  • 5Murehy WK,Fossella FV,Winn RJ,et al.Phase Ⅱ study of taxol in patients with untreated advanced non-small cell lung cancer[J].J Natl Cancer Inst.1993.85:384-388.
  • 6Milas L,Hunter NR,Mason KA.Role of reoxygenation in induction of rehancenent of tumor radioresponse by paclitaxel[J].Cancer Res 1995.55:3564-3568
  • 7Spencer GM,Faukls D.Paclitaxel:a review of its phamacodynamic and phamacokinetic potential in the treatment of cancer[J].Drugs,1994,48:795-838.
  • 8Hainsworth JD,Greco FA.Paclitaxel administered by I hour infusion.Cancer 1994,74:1377-1382.
  • 9Levi F.Circadian Chronotherapy for Human Cancers[J].Lancet Oncol,2001,2 (5):307-315.
  • 10Granda TG,Fiilipski E,D' Attino RM,et al.Experimental Chronotherapy of Mouse Mammary Adenocarcinoma MA13/C with Docetaxel and Doxorubicine as Single Agent and in Combination[J].Cancer Res,2001,61 (5):1996-2001.

共引文献16

同被引文献43

  • 1蒋华,姜维美,刘燕文.时辰化疗与肿瘤患者生活质量关系的研究[J].中华肿瘤防治杂志,2008,15(9):699-702. 被引量:8
  • 2李张珂,李延辉,王凡,尹磊,牛占峰,夏鹤春.大鼠胶质瘤细胞中生物钟基因Period2的生物节律性研究[J].宁夏医科大学学报,2013,35(5):485-488. 被引量:1
  • 3李颖,朱彬,王跃锜,华慧,何垠波,王正荣.节律基因Period2对肿瘤细胞生长及放射敏感性的影响[J].航天医学与医学工程,2006,19(4):257-259. 被引量:4
  • 4周均田,邬麟,徐建华,胡炳强,殷先利,李旭英,曾毅栋,林荷梅,刘振洋.NP方案时辰化疗治疗非小细胞肺癌的临床研究[J].临床肿瘤学杂志,2007,12(8):583-586. 被引量:12
  • 5l.evi F, Schibler U. Circadian rhythms: mechanisms and therapeutic implications [J]. Annu Rev Pharmacol Toxicol, 2007,47:593- 628.
  • 6Filipski E,King VM, I.i XM, et al. Host circadian clock as a control point in tumor progression[-J]. Journal of the National Cancer Institute,2002,94(9) :690-697.
  • 7Rosbash M, Takahashi JS. Circadian rhythms~ the cancer connection[J]. Nature,2002,420(6914) :373 -374.
  • 8L6vi F. Circadian chronotherapy for human cancers[J]. The lancet Oncology,2001,2(5) :307 -315.
  • 9Abolmaali K, Balakrishnan A, Stearns AT, et al. Circadianvariation in intestinal dilwdropyrimidine dehydrogenase (DPD) expression: A potential mechanism for benefits of 5FU chrono chemotherapy[J]. Surgery, 2009,146 (2) : 269-273.
  • 10Gallion HH, Brunetto VI., Cibull M, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin instage 1II and IV or recurrent endometrial carcinoma: a G-ynecologic Oneology Group Study[J]. Journal of Clinical Oncology, 2003,21 ( 20 ) : 3808 -3813.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部